胆道癌综述:病因、诊断、分子分型与治疗进展
胆道癌包括肝内、肝门周围及远端胆管癌和胆囊癌,在高收入国家发病率低但全球肝内胆管癌发病率上升。手术是治愈基石,但多数患者确诊时已为局部晚期或转移性疾病。分子分型(如IDH1突变、FGFR2融合)正改变治疗格局,本综述更新了病因、诊断、分子分类和治疗。
要点
- 手术是治愈基石,最佳方案取决于原发肿瘤解剖部位,多学科团队管理可获最佳结局。
- 多数晚期患者需 pooling 不同亚型以达到足够样本量,但各亚型流行病学、治疗反应和预后差异显著。
- IDH1突变和FGFR2融合等分子改变对应靶向治疗,正在改变肝内胆管癌治疗范式。
核心结论
- 胆道癌各亚型在流行病学、临床表现、自然史、手术、治疗反应和预后上存在差异,分子分型正推动靶向治疗发展。
研究设计与样本
- 本文为Seminar综述,更新胆道癌的病因、诊断、分子分类和治疗。
主要发现
- 肝内胆管癌发病率全球上升。
- 多数患者就诊时即为局部晚期或转移性疾病。
- 晚期研究常需汇总不同亚型以获得足够样本量。
- 识别出具有独特分子改变(如IDH1突变、FGFR2融合)的患者亚群并对应靶向治疗。
临床怎么用
- 手术方案应根据原发肿瘤解剖部位制定,并由专科多学科团队管理。
- 晚期胆道癌需考虑分子检测以识别可靶向的分子改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the optimal approach depends on the anatomical site of the primary tumour and the best outcomes are achieved through management by specialist multidisciplinary teams. Unfortunately, most patients present with locally advanced or metastatic disease. Most studies in advanced disease have pooled the various subtypes of biliary tract cancer by necessity to achieve adequate sample sizes; however, differences in epidemiology, clinical presentation, natural history, surgical therapy, response to treatment, and prognosis have long been recognised. Additionally, the identification of distinct patient subgroups harbouring unique molecular alterations with corresponding targeted therapies (such as isocitrate dehydrogenase-1 mutations and fibroblast growth factor receptor-2 fusions in intrahepatic cholangiocarcinoma, among others) is changing the treatment paradigm. In this Seminar we present an update of the causes, diagnosis, molecular classification, and treatment of biliary tract cancer.
引用
- Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021. PMID: 33516341. doi:10.1016/S0140-6736(21)00153-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。